CAR-T cells for relapsed B-cell cancers
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This early-phase trial tests a type of immunotherapy called anti-CD19 CAR-T cells. These are specially engineered immune cells that seek out and destroy cancer cells with a marker called CD19 on their surface. It is for people with B-cell cancers (leukemia or lymphoma) that have not responded to or come back after standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old.
- You have B-cell acute lymphoblastic leukemia (ALL) or a type of B-cell non-Hodgkin lymphoma (such as diffuse large B-cell lymphoma, mantle cell lymphoma, etc.) that has come back or not improved after standard treatments.
- You are willing to sign a consent form and follow all study procedures.
- Your overall health is good (ECOG performance status 0-2) and you are expected to live at least 12 weeks.
- Your blood counts and organ function (kidney, liver, heart, lungs) meet certain minimum levels, and you have no active serious infections or other cancers.
- You have not had a previous CAR-T cell therapy or certain other treatments within a specified time frame.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special type of immune therapy called CD19-BAFF CAR-T cells for people whose B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma has come back or not responded to standard treatment. The therapy uses your own modified immune cells to target and kill cancer cells.
This trial tests a new CAR-T cell therapy that targets a protein called CD19 on leukemia cells. It's designed for people with relapsed or refractory B-cell acute lymphoblastic leukemia (a type of blood cancer) that hasn't responded to standard treatments.
This trial tests a new type of immunotherapy called CAR-T cells, which are made from your own blood cells and trained to find and destroy leukemia cells. It is for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target and destroy leukemia or lymphoma cells that carry the CD19 or CD22 marker. It is for people whose cancer has not responded to other treatments or has returned.
This study tests a new type of immunotherapy that uses your own immune cells, modified in a lab, to find and attack cancer cells in blood cancers like leukemia, lymphoma, and multiple myeloma. It is for people whose cancer has come back or not responded to standard treatments.
This trial tests a type of immune treatment (CAR-T cells) for blood cancers that have come back or did not respond after standard treatments. It is for tumors that have CD19 on their cells, aiming to reduce the cancer and improve remission chances.
Hear when a new B Cell Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.